Financial Constraints to Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Alexander Bastian mentions that looking at more defined populations and leveraging the power of targeted medicine is improving the standard of care.
Hear as Dr Agarwala deliberates the impact of the Affordable Care Act on oncology care.